{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-039770","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.142556+00:00","generated_at":"2026-05-17T14:27:06.053080+00:00","sec_items":["1.01","3.02","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"X4 Pharma raises $60M, CEO and CFO resign, new leadership team appointed","bullets":["Private placement of 11,040,776 shares at $1.42/share and pre-funded warrants for 31,234,731 shares for ~$60M gross.","CEO Paula Ragan, Ph.D., and CFO Adam S. Mostafa resigned effective Aug 12, 2025; no disagreement cited.","Adam Raymond Craig, M.D., Ph.D., appointed Executive Chairman and principal executive officer; John Volpone named President.","David H. Kirske appointed CFO, Secretary, principal financial and accounting officer.","Proceeds to fund continued development of mavorixafor for chronic neutropenia and commercialization for WHIM."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-039770","json":"https://secwatch.observer/filing/0001628280-25-039770.json","markdown":"https://secwatch.observer/filing/0001628280-25-039770.md","text":"https://secwatch.observer/filing/0001628280-25-039770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025039770/0001628280-25-039770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025039770/xfor-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:27:06.053080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}